<qa>  What is the CCQ?2.6 Data Analysis. Data will be subjected to separate ANOVAANCOVA procedures SPSS, IBM Corp., Armonk NY. For each paradigm, endpoint measures will be analyzed by mixed ANOVAs, with between-group 2 levels: patients, controls and within-grouprepeated measures factors including drug caffeine, placebo. Analysis of EEGERP endpoints will also include scalp site as a within-group factor. Daily caffeine consumption as measured by the CCQ will be used as a covariate. Follow-up of significant Greenhouse-Geisser corrected main or interaction effects p .05 will be carried out with Bonferroni-adjusted planned comparisons using separate vs. pooled error estimates. In order to examine the correlation between behaviouralelectrophysiological endpoints and measures of caffeine consumption, two-tailed Spearmans rho correlations will be conducted between consumption measures and ERP amplitudeslatencies under placebo and drug conditions, as well as between consumption measures and measures of drug-associated change in ERP endpoints overall and within both groups. 